-transparent.png){kind=logo}
Using 2 radioimmunoassays, increased serum levels of amino-terminal type III procollagen peptide and its degradation products were demonstrated in rheumatoid arthritis patients. Patients with active disease showed higher serum propeptide levels than did patients with inactive disease. Unlike D-penicillamine, azathioprine treatment suppressed the propeptide levels in patients with active disease. A 6-month prospective study showed significantly higher initial serum propeptide levels in patients with erosive progression. The propeptide level reflects disease activity and may be a valuable prognostic marker in rheumatoid arthritis.
Related Publications
K Hørslev-Petersen, and
K D Bentsen, and
P Junker, and
I Lorenzen
January 1990,
Clinical and experimental rheumatology,
K Hørslev-Petersen, and
K D Bentsen, and
P Junker, and
I Lorenzen
March 1993,
Medicina clinica,
K Hørslev-Petersen, and
K D Bentsen, and
P Junker, and
I Lorenzen
December 1992,
Clinical rheumatology,
K Hørslev-Petersen, and
K D Bentsen, and
P Junker, and
I Lorenzen
December 2009,
Heart (British Cardiac Society),
K Hørslev-Petersen, and
K D Bentsen, and
P Junker, and
I Lorenzen
January 1987,
Hepatology (Baltimore, Md.),
K Hørslev-Petersen, and
K D Bentsen, and
P Junker, and
I Lorenzen
January 1992,
Experimental lung research,
K Hørslev-Petersen, and
K D Bentsen, and
P Junker, and
I Lorenzen
April 1989,
British journal of rheumatology,
K Hørslev-Petersen, and
K D Bentsen, and
P Junker, and
I Lorenzen
January 1994,
American journal of hypertension,
K Hørslev-Petersen, and
K D Bentsen, and
P Junker, and
I Lorenzen
July 1987,
Taiwan yi xue hui za zhi. Journal of the Formosan Medical Association,
K Hørslev-Petersen, and
K D Bentsen, and
P Junker, and
I Lorenzen
April 1992,
Alcoholism, clinical and experimental research,
